HUMIRA® for HCPs
SkyRizi™ for HCPs
RINVOQ™ for HCPs

The NEW IL-23 inhibitor from AbbVie indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy1

Resources for Patient Access and Support

Download forms to help patients get the support they need to start and stay on track with SKYRIZI

Practice forms and resources


Skyrizi complete enrollment

Once you and your patient complete the Skyrizi Complete Enrollment and Prescription Form, simply fax it to Skyrizi Complete and inform your patient that they will be receiving a call from their Nurse Ambassador. If you complete the Pharmacy Prescription, also fax it to your patient’s chosen specialty pharmacy.

Access and reimbursement forms

Skyrizi Complete is here to help your patients get timely access to SKYRIZI. Along with requesting information from a Skyrizi Complete Access Specialist, you can download the forms you need to get started.


TEMPLATES



Billing and Coding


SPECIALTY PHARMACY

Download forms to help patients get the support they need to start and stay on track with SKYRIZI

Patient forms and resources


Skyrizi complete enrollment

Once you and your patient complete the Skyrizi Complete Enrollment and Prescription Form, simply fax it to Skyrizi Complete and inform your patient that they will be receiving a call from their Nurse Ambassador. If you complete the Pharmacy Prescription, also fax it to your patient’s chosen specialty pharmacy.


Additional resources

looking for more resources?Offer enrollment to patients and submit forms
electronically with CompletePro.com

By registering through CompletePro.com, you can choose the
capabilities that are most relevant to you and your patients' needs, such as:

Instant benefits verification:

  • Patient out-of-pocket costs
  • Any prior authorization requirements
  • Pharmacy options available to the patient
  • Patient eligibility for any drug discount from the pharmaceutical company

Online prescribing efficiencies:

  • Complete a Prior Authorization and send it directly to the insurer
  • Send a prescription directly to the patient's chosen pharmacy
  • Send Skyrizi Complete Savings Card to your patient's preferred specialty pharmacy (with or without a prescription)
  • Be notified via text, email, or website in advance of patient's prior authorization expiration
  • Easily access each patient's prescription fill status

Stay up to date on the latest SKYRIZI news and information


Sign up to receive the latest SKYRIZI news and information

Get Skyrizi complete

Resources for your patients

Find out more about Skyrizi Complete resources for your patients

Only 4 doses per year

3-month dosing after 2 initiation doses at Weeks 0 and 41

View the SKYRIZI dosing schedule
IMPORTANT SAFETY INFORMATION AND INDICATION1
Indication

SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Important Safety Information

Infection

SKYRIZI may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)

Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.

Immunizations

Prior to initiating SKYRIZI, consider completion of all age appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with SKYRIZI.

Adverse Reactions

Most common (≥1%) adverse reactions associated with SKYRIZI include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections. 

US-SKZ-190144

REFERENCE

  1. SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.
IMPORTANT SAFETY INFORMATION AND INDICATION1
Infection SKYRIZI™ may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated. Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.
IMPORTANT SAFETY INFORMATION AND INDICATION1
Infection SKYRIZI™ may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves
IMPORTANT SAFETY INFORMATION AND INDICATION1
Infection SKYRIZI™ may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated. Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.
IMPORTANT SAFETY INFORMATION AND INDICATION1
Infection SKYRIZI™ may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves
IMPORTANT SAFETY INFORMATION AND INDICATION1
Indication

SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Important Safety Information

Infection

SKYRIZI may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)

Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.

Immunizations

Prior to initiating SKYRIZI, consider completion of all age appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with SKYRIZI.

Adverse Reactions

Most common (≥1%) adverse reactions associated with SKYRIZI include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections. 

US-SKZ-190144